Lilly partners with Samsung Biologics to manufacture COVID-19 antibodies

By The Science Advisory Board staff writers

November 17, 2020 -- Eli Lilly and Samsung Biologics have signed a long-term partnership for manufacturing of Lilly's COVID-19 antibody therapies.

After the deal was initially signed in May, Samsung delivered an initial supply of active pharmaceutical ingredients (APIs) meeting good manufacturing practice (GMP) and regulatory expectations within five months, the firm said. What's more, technology transfer was completed in less than three months, according to Samsung.

The agreement supplements Lilly's internal manufacturing capacity.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.